Fosun International reported a strong recovery in the first half of 2026, with profit attributable to owners of the parent rising 160.3 per cent year-on-year to RMB1.72 billion, as its pharmaceuticals and insurance businesses delivered solid growth.
Guo Guangchang, Chairman of Fosun International, said the company’s results reflected the impact of strategic adjustments undertaken over the past few years, including a focus on core businesses and balance-sheet strengthening. “The strong results recovery we delivered in the first half of the year reflects the outcome of the strategic adjustments we have made over the past few years,” he said, adding that the company’s “repairing the roof on a sunny day” strategy had helped put historical burdens behind it and marked the beginning of a trajectory of steady growth.
During the reporting period, Fosun International recorded total revenue of RMB86.96 billion. Overseas revenue reached RMB49.16 billion, accounting for 56.5 per cent of total revenue, while the total debt-to-total capital ratio declined to 55.7 per cent.
The results were within the upper-middle range of the company’s profit alert issued on 29 July, which had forecast profit attributable to owners of the parent of approximately RMB1.5 billion to RMB1.8 billion, representing a year-on-year increase of approximately 127 per cent to 172 per cent.
Fosun’s four core businesses — Fosun Pharma, Yuyuan, Fosun Insurance Portugal (Fidelidade) and Tourism — generated combined revenue of RMB63.88 billion during the first half, representing 73.5 per cent of the Group’s total revenue.
The pharmaceutical business remained a key contributor to growth. Fosun Pharma reported operating revenue of RMB20.377 billion, while revenue from innovative drugs increased 13.84 per cent year-on-year. Innovative drugs accounted for 33.35 per cent of pharmaceutical business revenue, reinforcing their position as a major growth engine.
Henlius, Fosun Pharma’s innovative biopharmaceutical platform, recorded revenue of RMB3.5882 billion, up 27.3 per cent year-on-year. Net profit reached RMB430.4 million, an increase of 10.3 per cent.
Fosun Pharma also continued to expand the commercialisation of its innovative medicines. During the reporting period, seven innovative drugs received approval for a total of 20 indications in domestic and overseas markets.
Fosun’s insurance operations also recorded significant improvements across domestic and international markets.
Fidelidade, Fosun’s Portugal-based insurance business, achieved an overall market share of 30.1 per cent in Portugal, while its international business accounted for 26.7 per cent of consolidated total business. Net profit attributable to owners of the parent rose 23.8 per cent year-on-year to EUR165 million.
In mainland China, Pramerica Fosun Life Insurance recorded gross written premiums of RMB8.38 billion, representing a 52.2 per cent year-on-year increase. Net profit reached RMB780 million, up 270 per cent year-on-year and exceeding its full-year 2025 net profit.
Fosun United Health Insurance reported a 36.2 per cent increase in revenue and net profit of RMB572 million. Meanwhile, Peak Reinsurance recorded a 25 per cent increase in reinsurance revenue and an 11.8 per cent rise in gross written premiums, with net profit after tax reaching $89.70 million.
The company said its strategic focus in recent years has included streamlining operations and concentrating resources on core businesses. Since 2022, Fosun has divested assets and businesses and generated cumulative cash proceeds of approximately RMB75 billion.
At its 2025 annual results presentation, Guo Guangchang described the restructuring as “repairing the roof on a sunny day”, aimed at enabling the Group to direct resources towards core, high-growth businesses.
Looking ahead, Fosun said the stronger performance of its core businesses provides a foundation for continued growth, with pharmaceuticals and insurance expected to remain important contributors to its development.
